Switch theme
Sign up to access all valuation multiples
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.
1995
26.2K+
LTM Revenue $2.8B
LTM EBITDA $814M
$10.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zydus Lifesciences has a last 12-month revenue (LTM) of $2.8B and a last 12-month EBITDA of $814M.
In the most recent fiscal year, Zydus Lifesciences achieved revenue of $2.6B and an EBITDA of $832M.
Zydus Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zydus Lifesciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Profit | $2.0B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $814M | XXX | $832M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $708M | XXX | $700M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $544M | XXX | $530M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $274M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zydus Lifesciences's stock price is INR 930 (or $11).
Zydus Lifesciences has current market cap of INR 936B (or $11.0B), and EV of INR 885B (or $10.4B).
See Zydus Lifesciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.4B | $11.0B | XXX | XXX | XXX | XXX | $0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zydus Lifesciences has market cap of $11.0B and EV of $10.4B.
Zydus Lifesciences's trades at 4.1x EV/Revenue multiple, and 13.1x EV/EBITDA.
Equity research analysts estimate Zydus Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zydus Lifesciences has a P/E ratio of 20.1x.
See valuation multiples for Zydus Lifesciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.0B | XXX | $11.0B | XXX | XXX | XXX |
| EV (current) | $10.4B | XXX | $10.4B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 13.1x | XXX | XXX | XXX |
| EV/EBIT | 14.6x | XXX | 15.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.1x | XXX | 21.5x | XXX | XXX | XXX |
| EV/FCF | 21.1x | XXX | 20.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZydus Lifesciences's last 12 month revenue growth is 7%
Zydus Lifesciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $46K for the same period.
Zydus Lifesciences's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zydus Lifesciences's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zydus Lifesciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $46K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zydus Lifesciences acquired XXX companies to date.
Last acquisition by Zydus Lifesciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Zydus Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zydus Lifesciences founded? | Zydus Lifesciences was founded in 1995. |
| Where is Zydus Lifesciences headquartered? | Zydus Lifesciences is headquartered in India. |
| How many employees does Zydus Lifesciences have? | As of today, Zydus Lifesciences has 26.2K+ employees. |
| Is Zydus Lifesciences publicy listed? | Yes, Zydus Lifesciences is a public company listed on BOM. |
| What is the stock symbol of Zydus Lifesciences? | Zydus Lifesciences trades under 532321 ticker. |
| When did Zydus Lifesciences go public? | Zydus Lifesciences went public in 2000. |
| Who are competitors of Zydus Lifesciences? | Similar companies to Zydus Lifesciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zydus Lifesciences? | Zydus Lifesciences's current market cap is $11.0B |
| What is the current revenue of Zydus Lifesciences? | Zydus Lifesciences's last 12 months revenue is $2.8B. |
| What is the current revenue growth of Zydus Lifesciences? | Zydus Lifesciences revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Zydus Lifesciences? | Current revenue multiple of Zydus Lifesciences is 3.8x. |
| Is Zydus Lifesciences profitable? | Yes, Zydus Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zydus Lifesciences? | Zydus Lifesciences's last 12 months EBITDA is $814M. |
| What is Zydus Lifesciences's EBITDA margin? | Zydus Lifesciences's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Zydus Lifesciences? | Current EBITDA multiple of Zydus Lifesciences is 12.7x. |
| What is the current FCF of Zydus Lifesciences? | Zydus Lifesciences's last 12 months FCF is $490M. |
| What is Zydus Lifesciences's FCF margin? | Zydus Lifesciences's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Zydus Lifesciences? | Current FCF multiple of Zydus Lifesciences is 21.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
